Article

High Affinity Chimeric Antigen Receptor with Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms

2021-02-04

Abstract excerpt

Tumor heterogeneity is a key reason for therapeutic failure and tumor recurrence in glioblastoma (GBM). Our chimeric antigen receptor (CAR) T cell (2173 CAR T cells) clinical trial ( NCT02209376 ) against Epidermal growth factor receptor (EGFR) variant III (EGFRvIII) demonstrated successful trafficking of T cells across the blood brain barrier into GBM active tumor sites. However, CAR T cell infiltration was asso...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bef0d2f9-ffcd-5da2-b7ea-aa8e6d19fe69
DOI: 10.1101/2021.02.04.429797

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

High Affinity Chimeric Antigen Receptor with Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic IsoformsDOI 10.1101/2021.02.04.429797Read

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastomaSemantic proximity Read

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in GlioblastomaSemantic proximity Read

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.Semantic proximity Read

Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escapeSemantic proximity Read

Analysis of tumor-derived and cross-presented peptide antigens defines improved immunotherapeutic strategiesSemantic proximity Read

Gene Targets of CAR-T Cell Therapy for GlioblastomaSemantic proximity Read

The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.Semantic proximity Read

Epidermal growth factor receptor and variant III targeted immunotherapySemantic proximity Read

Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFRY1068 Phosphorylation.Semantic proximity Read

Application of blood brain barrier models in pre-clinical assessment of glioblastoma- targeting CAR-T based immunotherapiesSemantic proximity Read

Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastomaSemantic proximity Read

GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activitySemantic proximity Read